Germany stakes its claim over Curevac
The German government will not get exclusive access to Curevac’s Covid-19 vaccine as part of its 23% stake purchase, the company insists.
Astrazeneca wants Gilead; or does it?
Five reasons why Astra should buy Gilead, and five why a move of this sort is pure fantasy.
Here come the anti-Covid antibodies
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.
Remdesivir delivers another perverse result
The antiviral is just about positive in a moderate Covid-19 study, but paradoxically only as a limited regimen.
Viiv’s HIV success shows PrEP is not everything
Gilead’s dominance of the HIV prevention market is set to be challenged by monotherapy.
Can Gilead make remdesivir pay?
Gilead has been rewarded handsomely, via share price gains, for its Covid-19 remdesivir work, but the potential costs should not be forgotten.
Remdesivir results pile up, but what do they all mean?
The latest addition to remdesivir’s Covid-19 dataset paints a confusing picture, but it's not necessarily bad.
The winds change again for Gilead and remdesivir
A world desperate to know whether remdesivir will blunt Covid-19 received another hint today, and this time the news was more encouraging.
Kevzara's Covid-19 setback shows need for hard evidence
As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.
